Epitomee Medical

What Epitomee Medical does

Epitomee Medical Ltd. is an Israel-based, publicly traded medical device company (TASE: EPIT; founded 2005; headquartered in Caesarea) that develops ingestible therapeutic devices built on a proprietary pH-triggered, shape-shifting hydrogel scaffold platform. Its lead commercial product, the Epitomee® Capsule, is a drug-free, self-administered swallowable capsule that unfolds into a semi-rigid triangular structure in the stomach, where it applies mechanosensory stimulation to induce satiety and earlier meal termination. The capsule received CE Mark in September 2020 and FDA 510(k) clearance in September 2024 for weight management in adults with BMI 25–40 kg/m², supported by the RESET pivotal trial (n=279 across 9 US sites, 55.5% of treated patients achieving ≥5% weight loss at 24 weeks, p<0.0001 vs. 35% threshold) and eight peer-reviewed publications covering the RESET and ELECT studies. The product is positioned as a non-systemic alternative to GLP-1 agonists and bariatric procedures, and as a complement to diet and exercise for the overweight segment previously excluded from anti-obesity medications.

The company operates a secondary platform — a Biologics Delivery Platform that uses a mucoadhesive matrix patch to orally deliver biologic APIs (antibodies, peptides, hormones, proteins) to the intestinal wall, intended for licensing to pharmaceutical and biotech partners. Epitomee monetizes the weight management capsule through prescription-driven distribution: a former exclusive global license to Nestlé Health Science was cancelled in late 2023, after which the company rebuilt distribution via an exclusive Israeli agreement with Rafa (August 2025; first shipment December 2025), a German regional distributor (updated December 2025; first European order March 2026), US online pharmacy partnerships (February 2026), and an integrated-care partnership with ReviveHealth (April 2026) targeting employer-sponsored health programs. Manufacturing is conducted in-house at a dedicated production facility in Israel. The company has no disclosed revenue and operates with 11–50 employees, having raised approximately $58M cumulatively through a $51M IPO on TASE in December 2021 and prior rounds.

Name

Epitomee Medical

Legal name

Epitomee Medical Ltd.

Website

https://epitomeemedical.com

Company type

Public

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

Epitomee Medical is an Israel-based medical device company that develops a drug-free, FDA-cleared ingestible hydrogel capsule (Epitomee® Capsule) that expands in the stomach to induce satiety for weight management in adults with BMI 25–40, distributed through regional partners (Rafa, US online pharmacies, German distributor) and integrated care platforms.

Ownership category

akta.pro rank

Product category

Ingestible Medical Devices for Weight Management

NAICS

Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ)

akta.pro secondary industry

Delivery Systems & Encapsulation (Microencapsulation, Liposomes, Emulsions, Beadlets, Spray-Dried) (AFAJAKAL)

Keywords

• Ingestible medical devices
• Weight management capsule
• Oral biologics delivery
• Hydrogel scaffold platform
• Obesity treatment devices

Headquarters

HQ city

Caesarea

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

1. Product Sales — Weight Management Capsule: Revenue from direct sales and distribution of the Epitomee Capsule for weight management. The product is sold by prescription through healthcare professionals, distributed via online pharmacies in the US, through Rafa in Israel, and through other regional distributors. Nestlé Health Science previously held global commercialization rights before the relationship was restructured.
2. Licensing and Distribution Agreements: The company generates revenue through licensing arrangements with distribution partners. The original Nestlé agreement was a strategic licensing and commercialization partnership. After Nestlé cancelled its license agreement in late 2023, the company established new distribution agreements with Rafa (exclusive Israel), US online pharmacies, and a German distributor.
3. Platform Technology Licensing — Biologics Delivery: Epitomee is seeking partnerships to enable its oral delivery platform to carry third-party APIs (active pharmaceutical ingredients) for optimized biologics administration. Revenue would come from licensing the delivery platform to pharma/biotech companies.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels7 records

Core offering

Epitomee Medical develops, manufactures, and commercializes the Epitomee® Capsule, an FDA-cleared and CE-marked drug-free, self-administered ingestible shapeshifting hydrogel capsule for weight management in adults with BMI 25-40. The company also operates a broader ingestible therapeutic device platform for oral delivery of biologic drugs, partnering with pharmaceutical and biotech companies to deliver APIs via mucoadhesive patches that deploy against the intestinal wall.

Product overview

Epitomee Medical is a medical device company offering ingestible therapeutic platforms. The portfolio consists of two core offerings: (1) the Epitomee® Capsule, an FDA-cleared and CE-marked weight management device that uses a shapeshifting hydrogel scaffold to induce satiety; and (2) a Biologics Delivery Platform designed for oral administration of biologic drugs via mucoadhesive patches that attach to the intestinal wall, offering a needle-free alternative to injections.

Differentiator

Problem solved

Functional benefit

Brands

• Epitomee® Capsule: FDA cleared and CE approved ingestible weight management capsule for adults with BMI 25-40 kg/m²

Products and services

• Epitomee® Capsule FDA-cleared and CE-marked ingestible medical device for weight management in adults with BMI 25-40 kg/m². A drug-free, self-administered shapeshifting capsule that expands in the stomach into a semi-rigid triangular configuration to create a sensation of fullness, inducing satiety and reducing caloric intake via twice-daily dosing before meals. Available by prescription through healthcare providers, regional distributors, and online pharmacies.
• Biologics Delivery Platform Oral delivery platform for biologic drugs using shape-shifting hydrogel scaffold technology. The platform enables targeted, protected delivery of biologic payloads (antibodies, peptides, hormones, proteins, small molecules, micronutrients) to the intestinal wall via a mucoadhesive matrix patch, offering a needle-free oral alternative to subcutaneous and IV injections. The company is seeking licensing partnerships with pharmaceutical and biotech companies.

Quantifiable outcome

• 55.5% of Epitomee-treated patients achieved ≥5% body weight loss at 24 weeks (P<0.0001 vs. 35% threshold)
• +7 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Four partnerships are on record, tiered strategic — integrated care model, core — exclusive israel distribution, former flagship — restructured and minor — operational support.

• ReviveHealthstrategic — integrated care modelStrategic or Co-development Partner · 9 April 2026ReviveHealth, a provider of integrated whole-person healthcare solutions, partnered with Epitomee to introduce the Epitomee Capsule as a non-pharmacological pathway within Revive's Weight Health program. The program targets employer-sponsored insurance members with a coaching-led, wraparound care model. The capsule is offered as a clinically guided option without stimulants, hormones, or surgical procedures.
• Rafa (רפא)core — exclusive israel distributionChannel Partner/ Reseller/ Distributor · 6 August 2025Rafa signed an exclusive distribution agreement (August 2025) for the marketing, distribution, and sale of Epitomee's weight loss capsule in Israel. First shipment to Rafa was delivered December 2025. Rafa is a significant Israeli pharmaceutical/healthcare distributor.
• Nestlé Health Scienceformer flagship — restructuredOEM/ Whitelabel/ Licensing Partner · 11 August 2020Nestlé Health Science and Epitomee entered into a strategic agreement (August 2020) to develop and commercialize the Epitomee weight loss and metabolic health product globally. Nestlé received exclusive global commercialization rights. Nestlé converted $7M as part of the IPO (December 2021). Nestlé cancelled the license agreement in late 2023 after RESET trial results reportedly did not fully meet contractual thresholds. An Israeli regulatory inquiry followed (Neto authorization opened August 2025). The company subsequently established alternative distribution channels including Rafa (Israel), US online pharmacies, and German distributor. The company presentation (May 2026) indicates Nestlé remains a key partner reference.
• PearlComminor — operational supportOthersPearlCom provides Strategy, UI & UX services for the Epitomee website and digital presence.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Novo Nordisk: Global leader in obesity pharmacotherapy with Wegovy and Saxenda (GLP-1 agonists). Represents the dominant incumbent alternative to Epitomee's drug-free approach and the principal competitive pressure shaping prescriber and payer behavior in the weight-loss category.
• Eli Lilly: Markets Mounjaro/Zepbound (tirzepatide) for obesity, currently the most effective approved pharmacotherapy. A broad incumbent whose commercial reach and clinical evidence base materially influence the strategic positioning of all non-GLP-1 weight-loss devices.
• Boston Scientific: Diversified global medical-device incumbent with adjacent obesity/metabolic health and GI device portfolios. Represents the type of strategic acquirer or large partner that could commercialize Epitomee's technology at scale.

Direct peers

• Obalon Therapeutics: Pioneered a swallowable, gas-filled intragastric balloon system for weight loss. Although the company wound down operations, it remains a historically relevant peer demonstrating the challenges and competitive dynamics of swallowable weight-management devices.
• Gelesis: Developed Plenity, an oral superabsorbent hydrogel capsule for weight management that expands in the stomach to induce satiety — the closest mechanistic and clinical analog to Epitomee's ingestible hydrogel capsule. Both target adults with overweight/obesity via a drug-free, mechanical mechanism and have pursued FDA clearance.
• Allurion Technologies: Maker of the Elipse swallowable gastric balloon for weight loss — a procedurally similar ingestible, self-administered weight-management device (though balloon-based rather than hydrogel-based). Targets a similar patient population through a comparable non-surgical, outpatient model.
• Rani Therapeutics: Develops the RaniPill, an ingestible capsule designed to deliver biologics (including peptides and antibodies) orally by injecting them into the intestinal wall. Directly comparable to Epitomee's Biologics Delivery Platform, which uses mucoadhesive matrix patches for the same therapeutic intent.

Emerging players

• Spatz Medical: Developer of the Spatz3 adjustable intragastric balloon for non-surgical weight loss. Operates in the same clinical weight-management device category as Epitomee, though using a balloon (endoscopically placed and adjustable) rather than an ingestible capsule.
• ReShape Lifesciences: Sells the ReShape Vest system and previously marketed the ReShape Intragastric Balloon for weight loss. Operates in the medical-device weight-loss category with overlapping customer segments (clinicians, integrated care providers).
• Lyndra Therapeutics: Develops long-acting oral drug delivery platforms, including ingestible capsules that slowly release drug payloads in the GI tract over days to weeks. Adjacent to Epitomee's oral biologics delivery efforts and a potential partner or competitor in oral sustained-release delivery.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Epitomee Medical